Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly.

ABSTRACT: The aging population, higher burden of predisposing conditions and comorbidities along with improvements in therapy all contribute to the growing prevalence of heart failure (HF). Although the majority of trials have not demonstrated age-dependent heterogeneity in the efficacy or safety of medical treatment for HF, the latest trials demonstrate that older participants are less likely to receive established drug therapies for HF with reduced ejection fraction. There remains reluctance in real-world clinical practice to prescribe and up-titrate these medications in older people, possibly because of (mis)understanding about lower tolerance and greater propensity for developing adverse drug reactions. This is compounded by difficulties in the management of multiple medications, patient prefere

SUBMITTER: Milinkovic I 

PROVIDER: S-EPMC9115638 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature